---
title: "Leqvio (inclisiran), all indications: Clinical trials questions"
description: "Clinical trials questions on Leqvio (inclisiran) that apply to every indication, each answered with verbatim quotes from the manufacturer's US website for healthcare professionals or documents it links. Topics: Study results. Questions: How quickly does Leqvio lower LDL-C after a dose? 1 question quoted from 2 sources."
canonical: "https://www.evicenter.com/medical-information/leqvio/clinical-trials"
published: "2026-11-14T01:54:55-05:00"
modified: "2026-11-14T01:54:55-05:00"
---

# Leqvio (inclisiran), all indications: Clinical trials questions

Manufacturer: Novartis Pharmaceuticals Corporation  
Prescribing information: [Leqvio](https://www.novartis.com/us-en/sites/novartis_us/files/leqvio.pdf)  
Indication pages: [Hypercholesterolemia](https://www.evicenter.com/medical-information/leqvio--hypercholesterolemia)

## Study results

<a id="leqvio-ldl-onset"></a>

### How quickly does Leqvio lower LDL-C after a dose?

> “Following a single subcutaneous administration of 284 mg of inclisiran, LDL-C reduction was apparent within 
> 14 days post dose. Mean reductions of 38% to 51% for LDL-C were observed 30 to 180 days post dose. At Day 
> 180, LDL-C levels were still reduced by approximately 53%.”

Source: [LEQVIO: Prescribing information, page 7, captured 2026-11-14](https://www.novartis.com/us-en/sites/novartis_us/files/leqvio.pdf#page=7)

> “In the ORION-1 phase 2 study, LDL-C reduction was apparent within 14 days after the first dose of LEQVIO<sup>1,10</sup>”

Source: [LEQVIO: Clinical Trial Data | LEQVIO® (inclisiran) | HCP, captured 2026-11-14](https://www.leqviohcp.com/efficacy/pivotal-trials#:~:text=In%20the%20ORION%2D1%20phase%202,after%20the%20first%20dose%20of)

> “Study Design: ORION-1 was a phase 2, multicenter, double-blinded, randomized, placebo-controlled clinical trial of 345 adults with established ASCVD who were taking a maximally tolerated statin and required additional LDL-C reduction. Of those, 91 patients received the 284-mg dose of LEQVIO. The primary efficacy end point was the percent reduction in LDL-C from baseline to Day 180 and was calculated for multiple time points at Days 14, 30, 60, 90, 120, 150, 180, 210, and 240.<sup>1,10</sup>”

Source: [LEQVIO: Clinical Trial Data | LEQVIO® (inclisiran) | HCP, captured 2026-11-14](https://www.leqviohcp.com/efficacy/pivotal-trials#:~:text=Study%20Design%3A%20ORION%2D1%20was%20a,120%2C%20150%2C%20180%2C%20210%2C%20and)

## Related pages
- [Medical information: Leqvio (inclisiran): All indications](https://www.evicenter.com/medical-information/leqvio)
- [Indication](https://www.evicenter.com/medical-information/leqvio/indication)
- [Pharmacology](https://www.evicenter.com/medical-information/leqvio/pharmacology)
- [Safety](https://www.evicenter.com/medical-information/leqvio/safety)
- [Specific populations](https://www.evicenter.com/medical-information/leqvio/specific-populations)
- [Drug interactions](https://www.evicenter.com/medical-information/leqvio/drug-interactions)
- [Dosing and administration](https://www.evicenter.com/medical-information/leqvio/dosing-and-administration)
- [Storage and supply](https://www.evicenter.com/medical-information/leqvio/storage-and-supply)
- [Access and coverage](https://www.evicenter.com/medical-information/leqvio/access-and-coverage)
